Intellia Therapeutics is trading 10.27% up at $12.79 after positive Phase 3 personalized mRNA cancer-vaccine results from Moderna and Merck lifted biotechnology sentiment.
- The trial met key goals in melanoma patients, while Moderna shares surged sharply.
- The developments supported broader enthusiasm for innovative drug-development platforms.
- No clear Intellia-specific announcement was identified on August 19, 2026; the move appears primarily sector-driven.